144 related articles for article (PubMed ID: 12895697)
21. HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41.
Cole AL; Yang OO; Warren AD; Waring AJ; Lehrer RI; Cole AM
J Immunol; 2006 Jun; 176(11):6900-5. PubMed ID: 16709850
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism.
Judice JK; Tom JY; Huang W; Wrin T; Vennari J; Petropoulos CJ; McDowell RS
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13426-30. PubMed ID: 9391041
[TBL] [Abstract][Full Text] [Related]
23. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
Baldwin CE; Sanders RW; Deng Y; Jurriaans S; Lange JM; Lu M; Berkhout B
J Virol; 2004 Nov; 78(22):12428-37. PubMed ID: 15507629
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
25. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
26. Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics.
Ni L; Gao GF; Tien P
Biochem Biophys Res Commun; 2005 Jul; 332(3):831-6. PubMed ID: 15913557
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
28. Capture of an early fusion-active conformation of HIV-1 gp41.
Furuta RA; Wild CT; Weng Y; Weiss CD
Nat Struct Biol; 1998 Apr; 5(4):276-9. PubMed ID: 9546217
[TBL] [Abstract][Full Text] [Related]
29. Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency.
Leung MY; Cohen FS
Biophys J; 2011 Apr; 100(8):1960-8. PubMed ID: 21504732
[TBL] [Abstract][Full Text] [Related]
30. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
31. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
32. Characterization of Gp41 polymorphisms in the fusion peptide domain and T-20 (Enfuvirtide) resistance-associated regions in Korean HIV-1 isolates.
Jang DH; Yoon CH; Choi BS; Chung YS; Kim HY; Chi SG; Kim SS
J Korean Med Sci; 2014 Mar; 29(3):456-9. PubMed ID: 24616600
[TBL] [Abstract][Full Text] [Related]
33. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
Tolstrup M; Selzer-Plön J; Laursen AL; Bertelsen L; Gerstoft J; Duch M; Pedersen FS; Ostergaard L
AIDS; 2007 Feb; 21(4):519-21. PubMed ID: 17301572
[No Abstract] [Full Text] [Related]
34. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
[TBL] [Abstract][Full Text] [Related]
35. The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.
Cunyat F; Marfil S; García E; Svicher V; Pérez-Alvárez N; Curriu M; Perno CF; Clotet B; Blanco J; Cabrera C
Retrovirology; 2012 Feb; 9():15. PubMed ID: 22333046
[TBL] [Abstract][Full Text] [Related]
36. The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide.
Covens K; Megens S; Dekeersmaeker N; Kabeya K; Balzarini J; De Wit S; Vandamme AM; Van Laethem K
Antiviral Res; 2010 Jun; 86(3):253-60. PubMed ID: 20227441
[TBL] [Abstract][Full Text] [Related]
37. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.
D'Arrigo R; Ciccozzi M; Gori C; Montieri S; Aquaro S; Bellagamba R; Boumis E; Di Perri G; Pizzi D; Antinori A; Rezza G; Perno CF
AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1296-302. PubMed ID: 17961119
[TBL] [Abstract][Full Text] [Related]
38. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
[TBL] [Abstract][Full Text] [Related]
39. Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains.
Eshleman SH; Hudelson SE; Bruce R; Lee T; Owens MR; Hackett J; Swanson P; Devare SG; Marlowe N
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1593-8. PubMed ID: 18160019
[TBL] [Abstract][Full Text] [Related]
40. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
